• Age\>18 years with no upper age limit

• Newly diagnosed multiple myeloma with indication for initiation of therapy.

• ECOG performance status 0-2

• No prior MM-directed therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 1000 mg/m2 and/or lenalidomide (up to 21 days of therapy) administered for no longer than 4 weeks prior to enrollment (pre induction). If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.

• Measurable disease meeting at least one of the following criteria (at screening or prior to pre induction):

∙ Serum monoclonal (M) protein ≥1.0 g/dl (≥0.5 g/dl if IgA, IgD, IgE or IgM multiple myeloma)

‣ ≥ 200 mg of M protein/24h in the urine

‣ Difference between affected and unaffected free light chain ≥10 mg/dL with abnormal kappa to lambda ratio.

• Have clinical laboratory values meeting the following criteria during the Screening Phase and also at start of administration of study treatment

∙ Hemoglobin ≥7 g/dL (≥4.65 mmol/L; without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted)

‣ Platelets ≥75×10\^9/L in participants in whom \<50% of bone marrow nucleated cells are plasma cells and ≥50×10\^9/L in participants in whom

• 50% of bone marrow nucleated cells are plasma cells (without transfusion support or thrombopoietin receptor agonist within 7 days before the laboratory test)

‣ Absolute neutrophil count ≥1.0×109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or GM-CSF and for 14 days for pegylated G CSF)

‣ AST and ALT ≤2.5×ULN

‣ eGFR ≥30 mL/min based on Modified Diet in Renal Disease Formula calculation or creatine clearance measured by a 24-hour urine collection

‣ Total bilirubin ≤2.0×ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤1.5×ULN is required)

‣ Serum calcium corrected for albumin ≤14 mg/dL (≤3.5 mmol/L) or free ionized calcium ≤6.5 mg/dL (≤1.6 mmol/L)

• A woman of childbearing potential must have a negative highly-sensitive serum pregnancy test at screening and again within 24 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study

• A woman must be

∙ Not of childbearing potential, or

‣ Of childbearing potential and

⁃ Practicing true abstinence; or

• Have a sole partner who is vasectomized; or

• Practicing ≥1 highly-effective, user-independent method of contraception

• A woman must agree not to donate eggs (ova, oocytes) or freeze for future use, for the purposes of assisted reproduction during the study and for 90 days after receiving the last dose of study treatment

⁃ A man must wear a condom (with or without spermicidal foam/gel/film/cream/suppository) when engaging in any activity that allows for passage of ejaculate to another person during the study and for a minimum of 90 days after receiving the last dose of study treatment. If a female partner is of childbearing potential, she must also be practicing a highly effective method of contraception

⁃ A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study treatment.

⁃ Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

⁃ Must sign an ICF (or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.

⁃ All participants must agree to comply with and be enrolled in Revlimid REMSTM program.

⁃ All participants must meet institution-specific criteria for AHCT eligibility as assessed by the investigator.

⁃ In line with the higher incidence of MM in Blacks, and to address the historical underrepresentation of ethnical minorities in MM trials, at least 25% of the enrolled patients will be of ethnical minorities.